SS-31 is a name used for elamipretide, a peptide developed in mitochondrial research. In 2025, the US FDA granted accelerated approval to Forzinity for a specific Barth syndrome indication. That decision does not approve every vial labelled SS-31.
What the research shows
Forzinity's indication covers improving muscle strength in adults and children with Barth syndrome weighing at least 30 kg. The accelerated decision used knee muscle strength as a surrogate endpoint and requires confirmatory clinical evidence. [1] [2]
Distinguishing substances and products
Forzinity evidence should not be extended to general energy, fatigue or anti-ageing promises. It also does not establish Thai registration or the quality of another manufacturer's product.
Reading a specific brand’s label
Start with the exact substance and product name, then match the label to the manufacturer’s documents. This article does not establish Thai registration or current availability for an unspecified product.
Frequently asked questions
Is there an approved elamipretide product?
Yes. US approval of Forzinity concerns a specific Barth syndrome indication, not all SS-31 products.
What does accelerated approval mean here?
The FDA relied on a surrogate endpoint and requires further confirmation of clinical benefit.
What information helps identify a specific product?
The brand, product name, full label and matching manufacturer documents. Evidence about the substance alone does not establish a product’s identity, registration or quality.
Related information
For general questions about names or label details, contact LINE: @musclestationth
Sources and review date
Sources checked: 11 September 2026. This page explains selected primary sources; it is not a systematic review of every study.